Uncategorized
A lame duck Congress reconvenes over stimulus
admin | November 6, 2020
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.
Congress reconvenes for a lame duck session on November 9 with both chambers putting a second stimulus bill high on the list of priorities. The two parties previously outlined their relief agendas in the Democrat proposed HEROES Act and the Republican sponsored HEALS Act. There is considerable overlap between the proposals despite a $2.3 trillion gap in spending. Agreement over some headline items—stimulus checks and unemployment insurance—should look like easy wins for both parties with horse trading coming over eviction moratoriums and loan modifications for homeowners and tenants, among other things.
Competing proposals for a second stimulus bill
Democrats in the House of Representatives outlined their priorities for a second coronavirus relief package in the Health and Economic Recovery Omnibus Emergency Solutions Act, or HEROES Act. The first version of the legislation (H.R. 6800) proposed a $3.4 trillion stimulus package. It passed the House on May 15 in a 208 to 199 vote, largely along party lines. One Republican voted in favor of the HEROES Act, Rep. Peter King of New York, a 14-term congressman not up for reelection. A group of 14 mostly moderate Democrats, many of whom faced tough races for reelection in districts that Trump won in 2016, voted against the legislation.
The Senate Republican counterpoint to the HEROES Act is the Health, Economic Assistance, Liability Protection and Schools, or HEALS Act, which was introduced by Senate Republicans on July 27. The HEALS Act is a group of eight bills providing $1.1 trillion in stimulus, which was intended to be the Republican starting point for negotiations for the next coronavirus relief bill.
- Safe to Work Act (S.4317)
- American Workers, Families, and Employers Assistance Act (S.4318)
- Supporting America’s Restaurant Workers Act (S.4319)
- Coronavirus Response Additional Supplemental Appropriations Act, 2020 (S.4320)
- Continuing Small Business Recovery and Paycheck Protection Program Act (S.4321)
- Safely Back to Work and Back to School Act (S.4322)
- Time to Rescue United States Trusts Act of 2020 (TRUST Act) (S.4323)
- Restoring Critical Supply Chains and Intellectual Property Act (S.4324)
The first HEROES Act did not come up for debate by the Senate, but negotiations between Democrats and Republicans continued. On October 1, the House passed a revised, somewhat scaled-back version of the HEROES Act (H.R. 925, as amended) in a near-party-line vote of 214 to 207, with 18 Democrats voting against it. The revised bill allotted $2.2 trillion for stimulus aid. The House Democrats published a detailed, title-by-title 87-page summary of the 2,000 page bill, as well as a 1-page overview.
There is an excellent side-by-side comparison of the HEALS Act vs the HEROES Act by law and lobbying firm GrayRobinson.
Election post-mortem
At this point, it appears that Democrat Joe Biden will be elected president by a narrow electoral margin. Republicans will likely maintain a razor-thin majority in the Senate, with two Senate races headed to January runoff elections. Republicans have whittled down the Democratic majority in the House by gaining five seats.
Among the group of House Democrats who opposed the Heroes Act were South Carolina Rep. Joe Cunningham, Iowa Rep. Abby Finkenauer, Oklahoma Rep. Kendra Horn, and New Mexico Rep. Xochitl Torres Small, all of whom lost their bids for reelection.
The five House Democrats who lost their bid for re-election included:
- Kendra Horn (D-OK) whose district was won by Trump in 2016.
- Collin Peterson (D-MN) whose Minnesota district Trump won in 2016 by the largest margin of any held by a Democrat.
- Freshman Rep. Abby Finkenauer (D-IA) also from a district in Iowa that Trump carried in 2016 but the Democrats flipped in 2018.
- Freshman Rep. Xochitl Torres Small (D-NM) who lost in a rematch to Yvette Herrell after Democrats flipped the district at the 2018 midterms.
- Joe Cunningham (D-SC) whose Charleston district flipped to the Democrats in 2018 after Republican Rep. Mark Sanford–an outspoken Trump critic–lost in the primaries. The district was retaken by Republican Rep. Nancy Mace who was the first woman to graduate from the Citadel.
Stimulus bill becomes top priority for lame duck session
Senate Majority Leader Mitch McConnell said on November 5 that Congress needs to pass another Covid-19 stimulus bill before January, and has made it his top priority when the legislature reconvenes on November 9. Based on the existing overlap between the HEALS and HEROES Acts, and ongoing bones of contention between the two parties, here are some guesses of the headline economic and market-based items that might be included in the new package.
What’s probably in:
- Another round of $1,200 direct stimulus checks to qualifying individuals and more generous payments for dependents. Democrats want payments of $1,200 per child while Republicans suggested $500 per dependent with no age limit.
- Renewal of enhanced unemployment insurance. Democrats want the $600 per week reinstated, while Republicans have proposed payments that replace only up to 70% of lost wages, up to $500 per week, when combined with state unemployment insurance payments.
- Expansion of Paycheck Protection Program loans, easier loan forgiveness terms and broader eligibility requirements for small businesses.
- Aid to states and local governments. This was not offered in the Republican HEALS Act. However, McConnell commented in a post-election press interview that such aid should be included in a new stimulus bill, though the amount will likely fall short of the $1 trillion sought by the Democrats in the HEROES Act.
- Money for a comprehensive coronavirus testing and tracing program.
- Easing of repayment terms for federal student loans.
What could be in:
- A liability shield for businesses to protect them from coronavirus-related lawsuits from workers and customers. This is a high priority for Republicans and is part of the HEALS Act, but does not appear in the HEROES Act.
- An extension of the moratorium on evictions and foreclosures; and a modification of CARES Act forbearance requirements with specific loan modifications and loss mitigation options available to homeowners. This was included in the HEROES Act but there was very little additional assistance provided to homeowners or renters in the HEALS Act.
- Assistance to airlines.
- Additional assistance to restaurants.
Notably absent:
- Any targeted provisions for commercial real estate owners or developers
Both of the proposed bills are expansive pieces of legislation that include funding or accommodations for laundry lists of party priorities, many of which have little or nothing to do with the pandemic. The Congressional horse trading during negotiations will hopefully eliminate most of the pork stuffing.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2025 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
Important disclaimers for clients in the EU and UK
This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).
The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.
This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.
This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.
This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.
